Lipid-Lowering Therapies Traditional lipid-lowering therapies statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, inclisiran, and bempedoic acid primarily reduce circulating apolipoprotein B (ApoB)containing lipoproteins, which both retards new atherogenesis and, at sufficient magnitude, drives angiographic plaque regression [15][17]
Does not affect IGF-1 or glucose levels
On day one of starting semaglutide GLP-1 , most individuals do not experience immediate appetite suppression
Salegio EA, Streeter H, Dube N et al (2014) Distribution of nanoparticles throughout the cerebral cortex of rodents and non-human primates: implications for gene and drug therapy
Hidden costs to watch for include initial consultation fees, required lab work, dose escalation pricing, and cancellation penalties